Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were enrolled because of age 65 years or older (elderly cohort). Both cohorts included patients with treatment-naive (TN) and re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Ahn, Inhye E., Farooqui, Mohammed Z. H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E. M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, Wiestner, Adrian
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969380/
https://ncbi.nlm.nih.gov/pubmed/29483101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-12-820910
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars